Ulrich-Pur Herbert, Jech Barbara, Scheithauer Werner, Kornek Gabriela Verena, Huber Heinz
Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin I, Wien, Osterreich.
Wien Klin Wochenschr. 2002 Jun 14;114(10-11):368-76.
Colorectal cancer represents one of the most common malignant diseases worldwide. Because of the expanding understanding of the biology of this disease entity, and the development/availability of a number novel antitumor agents, therapeutic options have considerably improved within the past few years. As for new drug development, therapeutic advances comprise the oral fluoropyrimidine prodrugs, specific thymidilate synthase inhibitors, irinotecan, oxaliplatin, and signal transduction inhibitors such as the anti-EGF-receptor monoclonal antibody Cetuximab. Compared to the area of conventional 5-fluorouracil therapy, much higher objective response rates and major improvements in overall survival can be achieved today, even in the case of disseminated disease. The aim of this review article is to provide the reader with an overview of presently available treatment options in the palliative, neoadjuvant and postoperative adjuvant setting in colon and rectal cancer, respectively. Furthermore, actual clinical-practice oriented and future perspectives in the management of this disease will be addressed.
结直肠癌是全球最常见的恶性疾病之一。由于对该疾病实体生物学的认识不断深入，以及多种新型抗肿瘤药物的研发和应用，在过去几年中，治疗选择有了显著改善。在新药研发方面，治疗进展包括口服氟嘧啶前体药物、特异性胸苷酸合成酶抑制剂、伊立替康、奥沙利铂以及信号转导抑制剂，如抗表皮生长因子受体单克隆抗体西妥昔单抗。与传统5-氟尿嘧啶治疗领域相比，如今即使是在疾病播散的情况下，也能实现更高的客观缓解率和总生存期的显著改善。这篇综述文章的目的是分别向读者概述目前在结肠癌和直肠癌的姑息治疗、新辅助治疗和术后辅助治疗中的可用治疗选择。此外，还将探讨该疾病管理中实际以临床实践为导向的内容和未来展望。
